All eyes will be on the first presentation of detailed results for Eisai Co., Ltd./Biogen, Inc.’s amyloid-clearing antibody lecanemab from the Phase III Clarity AD trial at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting from 29 November to 2 December in San Francisco. But data for other anti-amyloid therapies also may shed some light on what could make lecanemab stand out as it nears approval and launch.
Following Roche Holding AG’s announcement on 14 November that its anti-amyloid antibody gantenerumab failed to significantly best placebo in...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)